WHAT IS CLAIMED IS:

1. Use of etrasimod, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for the treatment of moderate to severe atopic dermatitis in a patient, wherein

the medicament is to be administered to a patient in need thereof;

a threshold absolute lymphocyte count (ALC) is to be identified in the patient;

the administration of the medicament is to be ceased for an interruption period of time; and

thereafter, the administration of the medicament is to be continued for a continuation period of time; and

wherein the patient in need thereof experiences an improvement in moderate to severe atopic dermatitis.

2. The use of claim 1, wherein the improvement in moderate to severe atopic dermatitis comprises an improvement in validated Investigator Global Assessment (vIGA) score, Eczema Area and Severity Index (EASI) score, or body surface area (BSA) score or in an improvement in a patient-reported outcome assessed using the Dermatology Life Quality Index (DLQI), Patient Oriented Eczema Measure (POEM), or Patient Global Assessment (PGA).

3. The use of any one of the preceding claims, wherein the medicament is to be administered at a frequency of once a day during the continuation period of time.

4. The use of any one of the preceding claims, wherein the medicament is to be administered in an amount equivalent to 2 mg or in an amount equivalent to 3 mg of etrasimod.

5. The use of any one of the preceding claims, wherein the threshold ALC is less than $500/mm^3$ or between 0.2 x 10e9 cells/L and 0.5 x 10e9 cells/L.

6. The use of any one of the preceding claims, wherein at least one of the interruption period of time is at least one week or the continuation period of time is at least one month.

7. The use of any one of claims 1-6, wherein the patient is diagnosed with moderate atopic dermatitis and has a vIGA score of 3 or the patient is diagnosed with severe atopic dermatitis and has a vIGA score of 4.

8. The use of any one of the preceding claims, further comprising the step of testing a circulating blood level of lymphocytes in the patient.

9. Use of etrasimod, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for the treatment of moderate to severe atopic dermatitis in a patient, wherein

the medicament is to be administered to a patient in need thereof;

the patient is to be monitored for one or more infections after administration of the medicament;

the administration of the medicament is to be ceased for an interruption period of time; and

thereafter, the administration of the medicament is to be continued for a continuation period of time;

wherein the treatment is therapeutically effective for moderate to severe atopic dermatitis.

10. The use of claim 9, wherein the medicament is to be administered at a frequency of once a day.

11. The use of any one of claims 9-10, wherein the etrasimod, or pharmaceutically acceptable salt thereof, is to be administered in an amount equivalent to 2 mg or 3 mg of etrasimod.

12. The use of any one of claims 9-11, wherein at least one of the interruption period of time is at least one week or the continuation period of time is at least one month.

13. The use of any one of claims 9-12, where in the patient is diagnosed with moderate atopic dermatitis and a vIGA score of 3 or is diagnosed with severe atopic dermatitis and has a vIGA score of 4.

14. The use of any one of claims 9-13, wherein the patient in need thereof comprises a body surface area (BSA) of atopic dermatitis greater than or equal to 10%.

15. The use of any one of claims 9-14, further comprising the step of monitoring the patient for infection a subsequent time after the interruption period, and, if an infection is identified, continuing to cease treatment.

16. The use of any one of claims 9-15, wherein the one or more infections is selected from urinary tract infection, ear infection, common cold, diptheria, E. coli, giardiasis, HIV/AIDS, mononucleosis, influenza, lyme disease, measles, meningitis, mumps, pneumonia, salmonella infections, respiratory infections, shingles, herpes, tuberculosis, viral hepatitis, or COVID-19.

17. The use of claim 1, further comprising:

the step of testing a circulating blood level of lymphocytes in the patient; and

wherein the interruption period of time is one day to four weeks.

18. Use of a pharmaceutical dosage form comprising a therapeutically effective amount of (R)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[*b*]indol-3-yl)acetic acid (Compound 1), or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for the treatment or amelioration of at least one symptom or indication of atopic dermatitis in an individual, wherein the medicament is to be administered in an amount equivalent to more than 2 mg to the individual in need thereof.

19. The use of claim 18, wherein an improvement to moderate to severe atopic dermatitis comprises an improvement in pruritus.

20. The use of claim 19, wherein the patient is diagnosed with moderate atopic dermatitis and has a vIGA score of 3 or the patient is diagnosed with severe atopic dermatitis and has a vIGA score of 4.